NuCana (NCNA) Liabilities and Shareholders Equity (2016 - 2025)
NuCana's (NCNA) quarterly Liabilities and Shareholders Equity came in at $39.7 million in Q4 2025, up 109.28% year-on-year from $19.0 million in Q4 2024, and down 8.99% quarter-over-quarter from $43.6 million in Q3 2025.
NuCana (NCNA) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends
NuCana has disclosed Liabilities and Shareholders Equity across 10 years of filings, most recently posting $39.7 million for Q4 2025.
- Liabilities and Shareholders Equity for Q4 2025 came in at $39.7 million, up 109.28% year-over-year; the trailing twelve-month figure through Dec 2025 was $119.5 million (up 18.19% YoY), and the FY2025 annual result was $39.3 million, up 108.29% from the prior year.
- Liabilities and Shareholders Equity came in at $39.7 million for Q4 2025 at NuCana, down from $43.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $139.1 million in Q1 2021 to a low of $14.6 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $47.6 million (2023), against an average of $61.7 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 109.28% in 2025, while the deepest fall reached 53.56% in 2025.
- NuCana's Liabilities and Shareholders Equity stood at $104.4 million in 2021, then sank by 34.57% to $68.3 million in 2022, then tumbled by 49.48% to $34.5 million in 2023, then plunged by 45.06% to $19.0 million in 2024, then soared by 109.28% to $39.7 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $39.7 million (Q4 2025), $43.6 million (Q3 2025), and $21.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 640.56 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 39.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.68 Mn |
| Sep 30, 2025 | 43.60 Mn |
| Jun 30, 2025 | 21.64 Mn |
| Mar 31, 2025 | 14.61 Mn |
| Dec 31, 2024 | 18.96 Mn |
| Sep 30, 2024 | 25.38 Mn |
| Jun 30, 2024 | 25.33 Mn |
| Mar 31, 2024 | 31.46 Mn |
| Dec 31, 2023 | 34.52 Mn |
| Sep 30, 2023 | 43.03 Mn |
| Jun 30, 2023 | 51.63 Mn |
| Mar 31, 2023 | 59.26 Mn |
| Dec 31, 2022 | 68.33 Mn |
| Sep 30, 2022 | 80.92 Mn |
| Jun 30, 2022 | 83.91 Mn |
| Mar 31, 2022 | 95.84 Mn |
| Dec 31, 2021 | 104.44 Mn |
| Sep 30, 2021 | 123.78 Mn |
| Jun 30, 2021 | 129.04 Mn |
| Mar 31, 2021 | 139.09 Mn |